MedTrace Logo

Appropriate Timing of HAART in Co-infected HIV/TB Patients

NCT01014481 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2011-11-17

No results posted yet for this study

Summary

To study the optimal timing to initiate antiretroviral therapy in HIV-infected patients who are receiving tuberculosis treatment between at 4 weeks and at 12 weeks after tuberculosis treatment by comparing the composite end point of death rate, hospitalization rate and adverse drug reactions at week 48, 96 and 144.

Conditions

Interventions

DRUG

tenofovir, lamivudine, efavirenz

initiate tenofovir 300 mg/day, lamivudine 300 mg/day, efavirenz 600 mg/day between at 4 weeks and at 12 weeks after tuberculosis treatment

Sponsors & Collaborators

  • Mahidol University

    collaborator OTHER

  • Thai Red Cross AIDS Research Centre

    collaborator OTHER

  • Bamrasnaradura Infectious Diseases Institute

    lead OTHER_GOV

Principal Investigators

  • Weerawat Manosuthi, MD · Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01014481 on ClinicalTrials.gov